Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Efficiency and safety of amantadine sulfate (AMS) infusions were investigated in late stage complications of Parkinson's disease (PD). In an open-label study, 21 PD patients suffering from motor fluctuations and/or dyskinesias were administered AMS infusions (PK-Merz, 400 mg per day) during seven days. Oral AMS treatment followed. Significant improvement of UPDRS motor scores was observed between day 0 and day 7, remaining improved until day 21. Based on patients' diary notes, both severity and occurrence of hypokinetic "off" state significantly decreased (from 6.6 to 3.1 hours, p < 0.001, average "off" time per day) as well as dopaminergic-induced dyskinesias (from 2.5 to 1.3 hours, p < 0.05, average duration of dyskinesias per day). AMS infusions followed by oral administration appeared as a safe method for improvement of both motor fluctuations and dyskinesias in advanced PD. In advantage to simple oral therapy, AMS infusions allowed fast introduction of a profound and durable treatment effect.
Růzicka
E
E
Movement Disorder Center, Department of Neurology, 1st Medical Faculty, Charles' University and General Teaching Hospital, Prague, Czech Republic. ruzicka@tremor.anet.cz
Streitová
H
H
Jech
R
R
Kanovský
P
P
Roth
J
J
Rektorová
I
I
Mecír
P
P
Hortová
H
H
Bares
M
M
Hejduková
B
B
Rektor
I
I
D000284:Administration, Oral; D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D012449:Safety; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D000547:Amantadine